A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older

Trial Profile

A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Pevonedistat (Primary) ; Azacitidine; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 15 Mar 2018 Planned End Date changed from 30 Nov 2017 to 23 Apr 2018.
    • 18 Jan 2018 Results assessing tolerability published in the Blood.
    • 06 Dec 2016 Updated safety and efficacy results for the maximum tolerated dose cohort presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top